<div id="readability-page-1">MEDIROM Healthcare Technologies ( (MRM) ) has released a notification of late filing.<h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul> Medirom Healthcare Technologies Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 20-F (Yearly Report) for the fiscal year ended December 31, 2025. The Tokyo-based wellness company, listed in the U.S., is pushing back its annual SEC filing for that period. The company says it cannot file the Form 20-F (Yearly Report) on time because the audit of its consolidated financial statements for 2025 is still in progress. Management notes that completing the audit and the related internal review would require unreasonable effort and expense within the original deadline. Medirom has not committed to the typical 15-day extension window under the applicable SEC rule, leaving the exact filing date open. Investors should assume the Form 20-F (Yearly Report) will be submitted once the audit work and management review are finalized, but without a precise timetable. Importantly for shareholders, the company does not expect any significant change in results of operations compared with the prior fiscal year. There is no indication in the filing of major restatements, unusual losses, or large swings in earnings, although all statements remain subject to completion of the audit and carry the usual forward-looking uncertainty. Medirom states that it has been current with all other required SEC reports over the past 12 months, signaling ongoing attention to compliance despite this delay. The notification is signed by Chief Financial Officer Fumitoshi Fujiwara, underscoring executive-level responsibility for completing the audit and bringing the Form 20-F (Yearly Report) filing back on schedule. Spark’s Take on MRM Stock According to Spark, TipRanks’ AI Analyst, MRM is a Neutral. The overall stock score is primarily influenced by financial performance and technical analysis. While the company shows strong revenue growth, profitability and liquidity challenges are significant concerns. The technical indicators suggest a bearish trend, but the stock appears undervalued based on its P/E ratio. To see Spark’s full report on MRM stock, click here. More about MEDIROM Healthcare Technologies Average Trading Volume: 316,416 Technical Sentiment Signal: Sell Current Market Cap: $9.48M </div>

Medirom Healthcare Technologies (MRM) has announced a delay in filing its Form 20-F (Yearly Report) for the fiscal year ending December 31, 2025, due to ongoing audits of its financial statements. The company has not committed to the typical 15-day extension and has left the exact filing date uncertain. However, it does not anticipate significant changes in operational results compared to the previous year. The CFO, Fumitoshi Fujiwara, signed the notification, emphasizing executive responsibility. Spark's analysis rates MRM stock as Neutral, highlighting revenue growth but concerns over profitability and liquidity.

Tip Ranks

Medirom Healthcare Tech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Genomics Immunology and Healthcare ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares US Healthcare Providers

iShares US Medical Devices

SPDR S&P Health Equip

Medirom Delays 20-F Yearly Report Filing